Bayonet Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 16-06-2024
- Paid Up Capital ₹ 1.00 M
as on 16-06-2024
- Company Age 10 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
as on 16-06-2024
- Revenue 39.34%
(FY 2023)
- Profit 190.80%
(FY 2023)
- Ebitda 297.39%
(FY 2023)
- Net Worth 31.71%
(FY 2023)
- Total Assets -0.62%
(FY 2023)
About Bayonet Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.00 M.
Maju Gopinathan, Anosh Chandran, Mahesh Geetha, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24100TN2014PTC095154
- Company No.
095154
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Feb 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Ambattur, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Bayonet Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoharan  | Managing Director | 24-Feb-2014 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Maju Gopinathan | Whole-Time Director | 04-Jan-2019 | Current |
| Anosh Chandran | Whole-Time Director | 04-Jan-2019 | Current |
| Mahesh Geetha | Whole-Time Director | 24-Feb-2014 | Current |
| Deepak Nair | Whole-Time Director | 24-Feb-2014 | Current |
| Girisan Karankara | Whole-Time Director | 24-Feb-2014 | Current |
Financial Performance and Corporate Structure Insights of Bayonet Pharmaceuticals.
Bayonet Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 39.34% increase. The company also saw a substantial improvement in profitability, with a 190.8% increase in profit. The company's net worth Soared by an impressive increase of 31.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bayonet Pharmaceuticals?
In 2023, Bayonet Pharmaceuticals had a promoter holding of 67.00% and a public holding of 33.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of Travancore Creation Date: 13 Jan 2016 | ₹2.00 M | Open |
How Many Employees Work at Bayonet Pharmaceuticals?
Unlock and access historical data on people associated with Bayonet Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bayonet Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bayonet Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
